Reflections on primary prevention from the ASPREE trial

2 pm – 3pm, February 19, 2019 | Seminar Room, Education Centre

This Burnet Institute event is part of the Institute’s WoI seminar series. 

Presenter: Professor John McNeil

Professor John McNeil AM, MBBS (Adelaide), MSc (London), PhD (Melbourne), FRACP, FAFPHM, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine.

Professor McNeil was Head of Monash Public Health and Preventive Medicine (SPHPM) at the Alfred Hospital from 1986 to January 2019. His principal expertise is in epidemiology and his research activities have typically involved the application of epidemiological methods to problems in clinical medicine and public health.

Under his leadership the SPHPM has experienced a sustained period of growth, increasing from 8 staff in 1986 to a current staff complement of over 700 (including 49 Professors). It contains core ‘methodology platforms’ in epidemiology, biostatistics and data-management which have enabled DEPM to establish itself as one of the major national centers of expertise in clinical trials and clinical registries.  The SPHPM is regularly involved in sensitive & urgent public health investigations such the Fiskville firefighters, the Hazelwood mine fire & the cancer clusters amongst Victorian Parliamentarians. In 2010 he was awarded membership of the Order of Australia in recognition of his services to public health.

The ASPREE Trial

ASPREE (ASPirin in Reducing Events in the Elderley) is an international clinical trial to determine whether daily low-dose aspirin increases survival, free of dementia and physical disability, for healthy older people. The randomised, double-blind, placebo-controlled study assesses aspirin for prevention of cardiovascular disease, dementia, depression and some cancers. It is being undertaken in more than 19,000 participants in Australia and the USA.